HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.

AuthorsDimitri Flieger, Sabine Hainke, Wolfgang Fischbach
JournalAnnals of hematology (Ann Hematol) Vol. 85 Issue 9 Pg. 631-2 (Sep 2006) ISSN: 0939-5555 [Print] Germany
PMID16807748 (Publication Type: Case Reports, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Organoplatinum Compounds
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Leucovorin
  • Fluorouracil
Topics
  • Adolescent
  • Adult
  • Aged
  • Angiogenesis Inhibitors (administration & dosage)
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Bevacizumab
  • Fluorouracil (administration & dosage)
  • Gastrointestinal Hemorrhage (drug therapy, etiology)
  • Humans
  • Leucovorin (administration & dosage)
  • Male
  • Mesothelioma (drug therapy, etiology)
  • Organoplatinum Compounds (administration & dosage)
  • Telangiectasia, Hereditary Hemorrhagic (complications, drug therapy)
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: